register

News & Trends - Pharmaceuticals

PBS process improvements impacted by COVID-19

Health Industry Hub | April 29, 2020 |

Pharma News: On 12 February 2020, the Department of Health hosted a webinar to commence broad consultation on proposed fee changes for Pharmaceutical Benefits Scheme (PBS) and National Immunisation Plan (NIP) listings.

This was followed by a public consultation period from 17 February to 16 March 2020.

As outlined at the webinar and in the consultation document, Stage 2 PBS process improvements and supporting cost recovery arrangements were to be implemented from 1 July 2020, pending Government agreement.

Overview of Stage 2 PBS Process Improvements

  1. Changes to initial submission categories (including introduction of a single submission date)
  2. Introduction of resubmission pathways for submissions not recommended by the PBAC
  3. Revised cost recovery arrangements to support implementation of Stage 2 process improvements.
  4. Other improvements, including IT system changes

You may also like PRIME Awards 2020 call for entries – the only awards program dedicated to recognising excellence within Australian healthcare communications, is now open for entries.

The current COVID-19 pandemic may impact the government approval of Stage 2 PBS process improvements and supporting cost recovery arrangements and a 1 July 2020 implementation date is now unlikely.

As a result, applicants should be prepared for the current processes and the 2020-21 fees indicated in the 2019-20 Cost Recovery Implementation Statement (CRIS) and the Regulations, pending government approval of some minor amendments, to commence from 1 July 2020.  These proposed 2020-21 fees were included in consultations last year.

A 2020-21 CRIS, which will outline the fees to apply from 1 July 2020 will be released as soon as possible.

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.